In last trading session, Castle Biosciences, Inc. (NASDAQ:CSTL) saw 1,417,996 shares changing hands. Company’s recent per share price level of $37.03 trading at -$2.3 or -6.04% at ring of the bell on the day assigns it a market valuation of $637.66 Million. That closing price of CSTL’s stock is at a discount of -20.25% from its 52-week high price of $44.53 and is indicating a premium of 58.79% from its 52-week low price of $15.26. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 345.73 Million shares which gives us an average trading volume of 189.23 Million if we extend that period to 3-months.

For Castle Biosciences, Inc. (CSTL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1. Splitting up the data highlights that, out of 4 analysts covering the stock, none rated the stock as a Sell while 1 recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 3 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.39 in the current quarter.

Castle Biosciences, Inc. (NASDAQ:CSTL) trade information

In the face of being in the red today for losing -6.04%, in the last five days CSTL remained trading in the green while hitting it’s week-highest on Friday, Jun 19 when the stock touched $44.53- price level, adding 16.84% to its value on the day. Castle Biosciences, Inc.’s shares saw a change of 7.74% in year-to-date performance and have moved -13.78% in past 5-day. Castle Biosciences, Inc. (NASDAQ:CSTL) showed a performance of -2.37% in past 30-days. Number of shares sold short was 1.29 Million shares which calculate 0.01 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $44.25 to the stock, which implies a rise of 19.5% to its current value. Analysts have been projecting $41 as a low price target for the stock while placing it at a high target of $47. It follows that stock’s current price would jump +26.92% in reaching the projected high whereas dropping to the targeted low would mean a loss of 10.72% for stock’s current value.

Castle Biosciences, Inc. (CSTL) estimates and forecasts

Statistics highlight that Castle Biosciences, Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company added +25.78% of value to its shares in past 6 months, showing an annual growth rate of 142.86% while that of industry is 9.5. Apart from that, the company came raising its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to increase by 62.9% in the current quarter and calculating -360% decline in the next quarter. This year revenue growth is estimated to rise 20.8% from the last financial year’s standing.

4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $9.05 Million for the same. And 4 analysts are in estimates of company making revenue of $16.27 Million in the next quarter that will end in September 01, 2020. Company posted $7.48 Million of sales in current quarter a year earlier. Analysts are expecting this quarter sales to grow by 21%.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 127.6% while estimates for its earnings growth in next 5 years are of 0%

Castle Biosciences, Inc. (NASDAQ:CSTL)’s Major holders

Insiders are in possession of 28% of company’s total shares while institution are holding 52.75% percent of that, with stock having share float percentage of 73.26%. Investors also watch the number of corporate investors in a company very closely, which is 122 institutions for Castle Biosciences, Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at CSTL for having 715.2 Thousand shares of worth $21.32 Million. And as of March 30, 2020, it was holding 4.15% of the company’s outstanding shares.

The second largest institutional holder is Highland Capital Management Fund Advisors, L.P., which was holding about 707.03 Thousand shares on March 30, 2020. The number of shares represents firm’s hold over 4.11% of outstanding shares, having a total worth of $21.08 Million.

On the other hand, Wasatch Ultra Growth Fund and Goldman Sachs Tr-Goldman Sachs Small/Mid Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of March 30, 2020, the former fund manager was holding 453603 shares of worth $13.52 Million or 2.63% of the total outstanding shares. The later fund manager was in possession of 261.72 Thousand shares on February 28, 2020, making its stake of worth around $7.84 Million in the company or a holder of 1.52% of company’s stock.